Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV milrinone for cerebral vasospasm after aneurysmal subarachnoid haemorrhage
ACTRN12622001405707Phase 2Terminated
- Sponsor
- Monash Medical Centre
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of milrinone in cerebral vasospasm (2 arms), sponsored by Monash Medical Centre. Primary endpoints: Total dose of milrinone administered and Total duration of milrinone administration. Started May 2023; status: terminated.
02
Drugs
milrinone
03
Conditions
cerebral vasospasm
Beyond the preview
Go deeper on ACTRN12622001405707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001405707.